Poolbeg Pharma plc
Notice of Results
28 February 2022 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company') a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, will announce its results for the period ended 31 December 2021 on Thursday 3 March 2022.
The Company will be hosting an online presentation for investors on the same day, at 6:00pm GMT on the Investor Meet Company platform.
The presentation is open to all existing and potential shareholders. Investors can register to attend here:
www.investormeetcompany.com/poolbeg-pharma-plc/register-investor
- Ends -
Enquiries
| Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O'Connell, CFO
| +44 (0) 207 183 1499 |
| finnCap Ltd (Nominated Adviser & Joint Broker) Geoff Nash, James Thompson, Charlie Beeson, Richard Chambers, Sunila de Silva (ECM)
| +44 (0) 207 220 0500 |
| Arden Partners PLC (Joint Broker) John Lewellyn-Lloyd, Louisa Waddell
| +44 (0) 207 614 5900 |
| J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist
| +353 (0) 1 679 6363 |
| Instinctif Partners Melanie Toyne Sewell, Rozi Morris, Tim Field
| +44 (0) 20 7457 2020
|
About Poolbeg Pharma
Poolbeg Pharma (AIM:POLB) is a clinical stage infectious disease pharmaceutical company with a capital light clinical model which is developing multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a "one-stop shop" for Big Pharma seeking mid-stage products to licence or acquire.
The Company is targeting the growing infectious disease market which has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.
Poolbeg has access to extensive knowledge, experience, and clinical data from over 20 years of human challenge trials through Open Orphan plc, an industry leading infectious disease and human challenge trials business. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk.
The Company continues to rapidly expand its portfolio of assets which currently includes POLB 001, a repositioned small molecule immunomodulator for severe influenza. POLB 002, a first-in-class, intranasally administered, RNA-based immunotherapy for respiratory virus infections and POLB 003, an intramuscular Melioidosis vaccine. The Company is also developing an oral vaccine delivery platform and as well as progressing its AI powered drug discovery program to identify pathways and drug candidates using its disease progression data.
For more information, visit www.PoolbegPharma.com or follow us @PoolbegPharma
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
